

### Poster No. P09-05

Antibodies to Protamine Sulfate or to its complexes with heparin can be the sole ones identified in some patients with suspicion of HIT. Amiral J., Vissac A.M. HYPHEN BioMed, Research, Neuville sur Oise (France)

# Introduction

Patients suspected of type II HIT, can present variable assay reactivities and variable clinical profiles, although the major group, with a typical presentation of HIT, has usually homogeneous positive results in immunoassays and platelet functional tests.

However, suspicion of HIT can be associated with atypical clinical presentations and laboratory assays can be difficult to interpret.

In this study we analyze the variability of antibody reactivity to various heparin binding antigens.

# **Materials and Methods**

➡85 patients with suspicion of type II HIT and with variable laboratory results. (discrepant assays) tested for antibodies binding to:

Heparin-protamine sulfate with or without platelet lysate;

Protamine sulfate (PS);

Bovine Serum Albumin (BSA);

Platelet Factor 4 (PF4);

**G**Heparin PF4 complexes (H-PF4)

## Aim

To analyze antibody binding to various heparin dependent antigens in atypical HIT, concerning patients with variable reactivities in laboratory assays, but with clinical presentations suggesting HIT (time of onset of platelet count decrease; thrombocytopenia; thrombosis; no other obvious cause of thrombocytopenia).

### **Patients**:

Medical and cardiology patients with suspicion of HIT during heparin therapy, and presenting variable reactivities in laboratory assays for HIT.

- Plates are saturated with goat serum.
- ➡Inhibition tests in presence of an excess of heparin (2 IU/mL), in the 1:100 diluted specimen, were performed.
- Only IgG isotypes were evaluated.
- ➡All plasma or serum specimen were assayed at 1:100 dilution in the assay diluent (containing 10% goat serum, for blocking non specific interactions).
- ➡All patients tested have a clear positive reactivity (A450 from >1.00 to > 3.00) for heparin dependent antibodies (IgG isotypes) tested with the Zymutest HIA, IgG kit (Binding to Heparin-Protamine-Sulfate complexes, in presence of platelet lysate).

### Results

#### **Antibody reactivity**

Patients (N=85) are classified according to antibody reactivity to the various capture antigens.

Antigen	Heparin-prota <u>With</u> Platele	amine sulfate <u>Without</u> t lysate	Protamine sulfate	BSA	PF4	Heparin PF4 complexes
+	85	16	16	0	47	63
_	0	70	69	85	38	22

#### Antibody profile in the 16 Patients reactive with Protamine Sulfate



Almost all patients with antibodies to Protamine Sulfate (16) are negative for their binding to Heparin PF4 complexes.

Only 2 out of the 16 patients have antibodies that bind also to H-PF4 (combined antibody reactivity, or capture of Protamine Sulfate-Heparinantibody complexes by immobilized H-PF4?)

inhibition studies for the binding to Heparin-Protamine Sulfate complexes (in presence of platelet lysate), performed with the plasma of **4** patients suspected of HIT:



Heparin in excess does not inhibit antibody binding to Protamine Sulfate-Heparincomplexes (or to Protamine Sulfate alone, data not shown), whether Platelet lysate is present or absent.

In typical HIT, excess of

totally

## Conclusions

Antibodies to protamine sulfate or to its complexes with heparin are the sole reactivity identified in some patients with suspicion of HIT and presenting its usual clinical associations (thrombocytopenia, kinetics of platelet count decrease, frequently thrombosis). These antibodies are suspected to be pathogenic, but further laboratory studies are required for demonstrating their implication. This adverse immune response requires further investigations.

These antibodies are not inhibited by heparin, as it is the case in typical heparin dependent antibodies in HIT.

Noteworthy, Protamine Sulfate antibodies are observed in a subset of patients presenting all the clinical symptoms of HIT. Most of them are from cardiology and had repeated exposures to Protamine Sulfate.

7768 Service Center Drive • West Chester OH 45069

inhibits



antibody binding.

heparin

Toll Free: 866.783.3797 Fax: 513.573.9241

Email: info@aniara.com

Form AH132 02-2010

www.aniara.com